Liver Cancer

Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus atezolizumab versus sorafenib in untreated hepatocellular carcinoma (HCC). The final analysis ...

Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last liver cancer patient treated under an Open-Label Extension program of its concluded Phase 2 study of Namodenoson experienced a Complete Response (CR). Under treatment with Namodenoson, the patient has now survived five years....

Merck & Co Inc (NYSE: MRK) has announced topline data from Phase 3 KEYNOTE-394 trial of Keytruda in Asian patients with advanced hepatocellular carcinoma (HCC). The trial included HCC patients previously treated with sorafenib. The study met its primary endpoint of overall...

Boston Scientific Corporation (NYSE: BSX) announced that the EPOCH clinical trial of the TheraSphere Y-90 Glass Microspheres (TheraSphere treatment) met both primary endpoints. The results of a long-term study showed that adding TheraSpheres to a standard chemotherapy regimen could...

Phio Pharmaceuticals Corp (NASDAQ: PHIO) has announced preclinical results from a new study of a self-delivering RNAi (INTASYL) therapeutic platform. The data were presented at the European Society of Medical Oncology (ESMO) Congress 2021. The study was performed to show the...

Bristol Myers Squibb & Co (NYSE: BMY) on Friday said it's voluntarily withdrawing Opdivo's approval in hepatocellular carcinoma (HCC) patients who previously received Bayer AG's (OTC: BAYRY) standard-of-care Nexavar. The decision came about three months after an...

Novocure Ltd (NASDAQ: NVCR) has announced final results from its phase 2 pilot HEPANOVA trial evaluating Tumor Treating Fields (TTFields) together with Bayer AG's (OTC: BAYRY) Nexavar (sorafenib) for hepatocellular cancer.  The trial enrolled 27 patients, and 21...

Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (Cabometyx) in combination with Roche Holding AG's Tecentriq (atezolizumab) versus Bayer AG's (OTC...

Surface Oncology (NASDAQ: SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC: RHHBY) to evaluate former's SRF388, anti-IL-27 antibody, in combination with Roche's atezolizumab and bevacizumab in patients with treatment-naïve...

Can-Fite BioPharma (NYSE: CANF) has completed pre-clinical studies demonstrating that a Cannabidiol (CBD)-rich T3/C15 cannabis fraction induces inhibition of liver cancer cell growth. The company's lead drug candidate Namodenoson is expected to enter the Phase 3 study in Q4...